CRMD Quote, Financials, Valuation and Earnings

NexGel has a net margin of 43.14% compared to Cormedix's net margin of -27.95%. Cormedix's return on equity of -28.22% beat NexGel's return on equity of -63.18%.

Cormedix has a consensus price target of $15.50, signalling upside risk potential of 128.28%. On the other hand NexGel has an analysts' consensus of $6.00 which suggests that it could grow by 129.01%. Given that NexGel has higher upside potential than Cormedix, analysts believe NexGel is more attractive than Cormedix.

Cormedix has a beta of 1.565, which suggesting that the stock is 56.522% more volatile than S&P 500. In comparison NexGel has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Cormedix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NexGel offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cormedix pays -- of its earnings as a dividend. NexGel pays out -- of its earnings as a dividend.

Cormedix quarterly revenues are $31.2M, which are larger than NexGel quarterly revenues of $3M. Cormedix's net income of $13.5M is higher than NexGel's net income of -$850K. Notably, Cormedix's price-to-earnings ratio is -- while NexGel's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cormedix is -- versus 1.96x for NexGel. Usually stocks with elevated PS ratios are considered overvalued.

PAVmed has a net margin of 43.14% compared to Cormedix's net margin of -1105.92%. Cormedix's return on equity of -28.22% beat PAVmed's return on equity of --.

Cormedix has a consensus price target of $15.50, signalling upside risk potential of 128.28%. On the other hand PAVmed has an analysts' consensus of $9.00 which suggests that it could grow by 1396.26%. Given that PAVmed has higher upside potential than Cormedix, analysts believe PAVmed is more attractive than Cormedix.

Cormedix has a beta of 1.565, which suggesting that the stock is 56.522% more volatile than S&P 500. In comparison PAVmed has a beta of 1.133, suggesting its more volatile than the S&P 500 by 13.28%.

Cormedix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PAVmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cormedix pays -- of its earnings as a dividend. PAVmed pays out -- of its earnings as a dividend.

Cormedix quarterly revenues are $31.2M, which are larger than PAVmed quarterly revenues of $10K. Cormedix's net income of $13.5M is higher than PAVmed's net income of $1.4M. Notably, Cormedix's price-to-earnings ratio is -- while PAVmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cormedix is -- versus 3.69x for PAVmed. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics has a net margin of 43.14% compared to Cormedix's net margin of --. Cormedix's return on equity of -28.22% beat Plus Therapeutics's return on equity of --.

Cormedix has a consensus price target of $15.50, signalling upside risk potential of 128.28%. On the other hand Plus Therapeutics has an analysts' consensus of $9.38 which suggests that it could grow by 1071.73%. Given that Plus Therapeutics has higher upside potential than Cormedix, analysts believe Plus Therapeutics is more attractive than Cormedix.

Cormedix has a beta of 1.565, which suggesting that the stock is 56.522% more volatile than S&P 500. In comparison Plus Therapeutics has a beta of 0.675, suggesting its less volatile than the S&P 500 by 32.459%.

Cormedix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cormedix pays -- of its earnings as a dividend. Plus Therapeutics pays out -- of its earnings as a dividend.

Cormedix quarterly revenues are $31.2M, which are larger than Plus Therapeutics quarterly revenues of --. Cormedix's net income of $13.5M is higher than Plus Therapeutics's net income of -$2.9M. Notably, Cormedix's price-to-earnings ratio is -- while Plus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cormedix is -- versus 0.98x for Plus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

X4 Pharmaceuticals has a net margin of 43.14% compared to Cormedix's net margin of -2776.92%. Cormedix's return on equity of -28.22% beat X4 Pharmaceuticals's return on equity of -82%.

Cormedix has a consensus price target of $15.50, signalling upside risk potential of 128.28%. On the other hand X4 Pharmaceuticals has an analysts' consensus of $2.79 which suggests that it could grow by 1156.68%. Given that X4 Pharmaceuticals has higher upside potential than Cormedix, analysts believe X4 Pharmaceuticals is more attractive than Cormedix.

Cormedix has a beta of 1.565, which suggesting that the stock is 56.522% more volatile than S&P 500. In comparison X4 Pharmaceuticals has a beta of 0.579, suggesting its less volatile than the S&P 500 by 42.116%.

Cormedix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. X4 Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cormedix pays -- of its earnings as a dividend. X4 Pharmaceuticals pays out -- of its earnings as a dividend.

Cormedix quarterly revenues are $31.2M, which are larger than X4 Pharmaceuticals quarterly revenues of $1.4M. Cormedix's net income of $13.5M is higher than X4 Pharmaceuticals's net income of -$39.8M. Notably, Cormedix's price-to-earnings ratio is -- while X4 Pharmaceuticals's PE ratio is 7.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cormedix is -- versus -- for X4 Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.